European patent granted for amatoxin conjugates for tumor therapy
The patent covers the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins.
The European Patent Office has granted Heidelberg a patent for its ADC technology for the manufacture of Antibody Amanitin Conjugates.
The patent is based on a patent application and named "Amatoxin armed therapeutic cell surface binding components designed for tumor therapy". The application was submitted by Professor Heinz Faulstich and employees of the German Cancer Research Centre (DKFZ). Heidelberg Pharma exclusively in-licensed the patent in December 2009.
The subject matter of the patent is the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins. Amatoxins are natural poisons occurring in, for example, the death cap mushroom (Amanita phalloides). To the company's knowledge, Heidelberg Pharma is the first company worldwide to work with the corresponding toxin amanitin to develop Antibody Targeted Amanitin Conjugates (ATACs) for the use in cancer therapy.
Amanitin is known in oncology for its unique mode of action: the inhibition of RNA polymerase II, which leads the cells to programmed cell death (apoptosis) independent from cell division. This offers the opportunity to treat therapy-resistant tumors and kill quiescent tumor cells, which could result in significant clinical progress.
The chemical linkage to natural amanitin is only possible at certain positions without loss of efficacy of the molecule. The granted European patent protects the use of certain positions for the ATAC technology which are chemically easy to access, and which maintain the biologic function of the Amanitin.
Prof Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma AG, commented: "We are delighted that, following the US patent, also the European patent has been granted to protect certain binding sites at our toxin amanitin. Since these binding sites at amanitin are protected independently of the structures linked to them, these patents offer strong protection of the natural substance Amanitin for use in ADC technology and protect our unique ATAC technology."
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance